Prior authorization for urology, GYN, and fertility, state by state

Urology and GYN PA is high-variety, moderate-volume work. A urology practice runs PAs for stone work, benign prostatic hypertrophy procedures, prostate biopsy, and incontinence implants in the same week. A GYN practice runs PAs for hysterectomy, ablation, fibroid treatment, and contraceptive implants. Fertility adds a separate layer with state-mandate complexity. This page walks all three.

Urology: TURP, lithotripsy, prostate, incontinence

BPH surgical work dominates urology PA. TURP (52601), Rezum (53854), UroLift (52441, 52442), Aquablation (0582T), and laser enucleation (HoLEP, 52649) all require documentation of BPH diagnosis, IPSS or AUA symptom score, failed medical therapy (alpha blockers, 5-ARIs, or combination), and prostate volume measurement. UroLift has a prostate-volume cap (most plans approve up to 80cc, some higher), so measurement documentation matters.

Kidney stone work (50590 ESWL, 52353 ureteroscopy with laser lithotripsy, 50080 percutaneous nephrolithotomy) requires imaging (CT, ultrasound), stone size and location, and often failed conservative management for smaller stones. Prostate biopsy (55700, 55706 MRI-fusion) usually requires PSA trend and often a prostate MRI with PI-RADS score. Prostate cancer surgery (55840, 55845, 55866 robotic prostatectomy) requires biopsy, Gleason score, staging, and multidisciplinary documentation.

Incontinence and pelvic-floor work (sling procedures 57288, sacral neuromodulation 64561 and 64581 InterStim) require failed conservative therapy, urodynamic studies, and trial documentation for neuromodulation.

Gynecology: hysterectomy, ablation, fibroid treatment

Hysterectomy (58150 abdominal, 58180 supracervical, 58260 vaginal, 58541-58544 laparoscopic, 58570-58573 laparoscopic total) is volume-heavy PA. Payers require documented indication (menorrhagia with failed medical therapy, fibroids with failed management, endometriosis, cancer, or prolapse), imaging, and for benign indications a documented trial of conservative therapy (often 3-6 months of hormonal management or IUD). Payers increasingly require a trial of endometrial ablation or myomectomy before hysterectomy for fibroids.

Endometrial ablation (58563) requires failed medical management, ultrasound confirming uterine size, and documentation that the patient has completed childbearing. Myomectomy (58140-58146, 58545-58546) requires fibroid imaging, size, and symptom documentation. Uterine fibroid embolization (37243) often routes through the IR pathway and shares PA elements with myomectomy.

Tubal ligation (58670, 58671) is covered as preventive under the ACA with no PA for most commercial plans. Contraceptive implants (11981 Nexplanon, J7297 Liletta, J7298 Mirena) are typically covered but benefit design varies.

OB and high-risk pregnancy

Routine prenatal care and delivery are bundled under the global OB fee and usually do not require PA. High-risk pregnancy interventions do: cervical cerclage (57700), amniocentesis and CVS (59000, 59015), fetal reduction (59866), antepartum testing (NST, BPP) in some plans, and the 17-hydroxyprogesterone caproate (Makena, J1726) pharmacy PA that still applies in some plans despite the drug's 2023 withdrawal. Cesarean section is bundled; VBAC is not PA'd differently. Maternal cardiology, endocrinology, and MFM consults follow standard specialty PA.

Reproductive endocrinology and IVF

Fertility PA is the most state-variable PA book in US healthcare. Twenty-one states have some form of fertility mandate, and they vary dramatically. New York, New Jersey, Massachusetts, Illinois, and Connecticut have relatively broad IVF mandates. Other states mandate only diagnostic coverage or limit by carrier type. Employer self-funded plans are ERISA and bypass state mandates, so the same carrier can have very different benefits on a fully-insured vs self-funded plan.

IVF PA typically runs per cycle. Payers require a specific diagnosis code (N97 female infertility, N46 male infertility) with documented workup, age (most mandates stop covering at 42-45), prior cycle history, and often a lifetime cycle cap. The medication PA is separate: Gonal-F, Follistim, Menopur, Cetrotide, Ganirelix, and trigger injections all route through a specialty pharmacy with different PA requirements. Preimplantation genetic testing (PGT-A, PGT-M) is often not covered by the mandate and is patient-pay.

Flexbone tracks the PA cycle against the IVF stimulation calendar, submits cycle PA ahead of stim start, coordinates medication PA with the specialty pharmacy, and handles the per-embryo transfer PA when applicable.

Payer and state-mandate rules

Full payer detail at commercial payers, BCBS plans, and Medicare, Medicaid, and government payers.

Urology and GYN EHRs

• Urology: Intergy Urology (Greenway), UroChart, eUroLogic, NextGen Urology, ModMed Urology.
• GYN: ModMed GYN, Digital Chart, athenahealth GYN, eClinicalWorks.
• Fertility: eIVF, IDEAS (Mellowood), Artisan, FertilityPro, Eva, Orcid Systems.
• ASC settings: ASC EHRs for PA.

How Flexbone handles urology, GYN, and fertility PA

The three sub-areas share one pattern: cycle-based or calendar-based PA. Urology has the BPH and stone cycle, GYN has the surgery and ablation cycle, fertility has the stim cycle. Flexbone reads the cycle from the EHR or fertility platform, runs PA ahead of the clinical event, and coordinates medication PA with the specialty pharmacy when applicable. See PA workflow and the platform.